Gilead Sciences (GILD) Prices $2B Notes Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Gilead Sciences (GILD) shares oversold argues BofA
September 8, 2023 8:54 AM EDTBofA analyst Geoff Meacham upgraded shares of Gilead Sciences (NASDAQ: GILD) to Buy from Neutral, with a price target of $95, up from $88 per share, in a note to clients on Friday.
The analyst told investors that the pharmaceutical company's HIV drug upside remains... More
